Here are the 10-K annual reports from Lisata Therapeutics, Inc. (LSTA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LSTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSTA filings page.
Lisata Therapeutics, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, executive compensation, ownership and governance that was omitted from the original filing. The company reports an aggregate market value of common stock held by non‑affiliates of about $23.6 million as of June 30, 2025, based on a Nasdaq price of $2.90 per share, and 9,106,391 shares outstanding as of April 28, 2026. The six‑member board is classified, with a majority deemed independent, and operates audit, compensation, nominating/governance, and science and technology committees. The filing discloses 2025 compensation for key executives, including total compensation of about $1.15 million for CEO David J. Mazzo, primarily salary and equity with no annual bonus, and describes severance and change‑in‑control protections. A forward‑looking statement section highlights risks such as a proposed acquisition by Kuva Labs, Inc., capital needs, ability to continue as a going concern, clinical trial execution and regulatory dependence.
Lisata Therapeutics, Inc. is a clinical-stage oncology company developing certepetide, a peptide designed to open a tumor-specific transport pathway so co-administered cancer drugs penetrate solid tumors more effectively with a favorable safety profile.
On March 6, 2026, Lisata agreed to be acquired by Kuva Labs Inc. via a tender offer in which shareholders will receive $5.00 in cash plus one non-tradeable contingent value right per share. The CVR pays $1.00 in cash if a New Drug Application or similar registration for any certepetide-containing product is filed or accepted before the earlier of seven years after closing or termination of the CVR agreement.
The offer is subject to a majority tender and other customary conditions, with closing expected in the second quarter of 2026. After the merger, Lisata will become part of privately held Kuva, its shares will be delisted from Nasdaq, and it plans to deregister as a reporting company.